Skip to content
BIO 2025: A few highlights from Day 1
Day 1 of BIO 2025 was all about collaboration: how industry can collaborate with the U.S. government to advance biodefense, how collaboration is key […]
BIO 2025: A few highlights from Day 1 Read More »
Biosecurity
BIO 2025: A strong biodefense requires government-industry partnerships
Biotech’s contribution to America’s biodefense can only be supported through public-private partnerships, but the public sector must provide adequate support and private actors need
BIO 2025: A strong biodefense requires government-industry partnerships Read More »
BIO hosts fly-in focused on biodefense, calls for PAHPA reauthorization
Over 30 representatives from biodefense companies joined the Biotechnology Innovation Organization (BIO) on Capitol Hill in November to meet with bipartisan congressional leaders to
BIO hosts fly-in focused on biodefense, calls for PAHPA reauthorization Read More »
BIO speaks on Capitol Hill about mpox preparedness
Mpox has proven to be a major public threat since its resurgence globally during the COVID years. As Bio.News reported, “On Aug. 14, the
BIO speaks on Capitol Hill about mpox preparedness Read More »
Exclusive: Sen. Todd Young on biosecurity, National Security Commission on Emerging Biotechnology (NSCEB)
Sen. Todd Young (R-IN) was recently named Chair of the National Security Commission on Emerging Biotechnology (NSCEB), established by Congress to recommend policy on biotech and national security.
I am BIO Podcast: Biotechnology is national security technology
American leadership in biotechnology is a vital national security asset in need of protection now, and its importance can be expected to grow in
I am BIO Podcast: Biotechnology is national security technology Read More »
Exclusive: Sen. Burr on the legacy of Project BioShield and the urgency of PAHPA reauthorization
2001 was the dawn of the modern era of biosecurity in the United States. Following the 9/11 attacks and deadly anthrax letters, the nation
FDA’s Dr. Califf talks supply chains, clinical trial diversity, and America’s health
Biopharma supply chains, streamlining regulation, and other critical issues came up when the leader of the U.S. agency regulating drugs spoke with the leader
FDA’s Dr. Califf talks supply chains, clinical trial diversity, and America’s health Read More »
Dr. Jason Kelly: Teaming up to build our bio future
Lately the world is enraptured with AI and its potential to change our lives. AI transforms our digital world—the world of information. But changing lives
Dr. Jason Kelly: Teaming up to build our bio future Read More »
BIO 2024: U.S. officials describe national security partnership with biotech
To ensure national security in the face of potential biological threats, the U.S. government relies on a partnership with biotech firms, federal officials explained
BIO 2024: U.S. officials describe national security partnership with biotech Read More »